159 related articles for article (PubMed ID: 1744683)
1. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Allalunis-Turner MJ; Day RS; McKean JD; Petruk KC; Allen PB; Aronyk KE; Weir BK; Huyser-Wierenga D; Fulton DS; Urtasun RC
J Neurooncol; 1991 Oct; 11(2):157-64. PubMed ID: 1744683
[TBL] [Abstract][Full Text] [Related]
2. Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Evans CG; Bodell WJ; Tokuda K; Doane-Setzer P; Smith MT
Cancer Res; 1987 May; 47(10):2525-30. PubMed ID: 2882834
[TBL] [Abstract][Full Text] [Related]
3. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
4. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model.
Sipos EP; Witham TF; Ratan R; Burger PC; Baraban J; Li KW; Piantadosi S; Brem H
Neurosurgery; 2001 Feb; 48(2):392-400. PubMed ID: 11220384
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
Reber U; Wüllner U; Trepel M; Baumgart J; Seyfried J; Klockgether T; Dichgans J; Weller M
Biochem Pharmacol; 1998 Feb; 55(3):349-59. PubMed ID: 9484802
[TBL] [Abstract][Full Text] [Related]
6. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
Shrieve DC; Harris JW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
[TBL] [Abstract][Full Text] [Related]
7. Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin.
Ito H; Rousseau V; Goavec M; Beaujean F; Morizet J; Stanislawski M
Cancer Lett; 1990 Feb; 49(2):169-73. PubMed ID: 2306711
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in response to treatment with buthionine sulfoximine or interferon in human malignant glioma cells.
Allalunis-Turner MJ; Barron GM; Day RS; Dobler K; Urtasun RC
Int J Radiat Oncol Biol Phys; 1992; 22(4):765-8. PubMed ID: 1544850
[TBL] [Abstract][Full Text] [Related]
9. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G
Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071
[TBL] [Abstract][Full Text] [Related]
10. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
Friedman HS; Colvin OM; Griffith OW; Lippitz B; Elion GB; Schold SC; Hilton J; Bigner DD
J Natl Cancer Inst; 1989 Apr; 81(7):524-7. PubMed ID: 2921776
[TBL] [Abstract][Full Text] [Related]
11. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
[TBL] [Abstract][Full Text] [Related]
12. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
13. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
16. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo.
Wick W; Stock J; Seyfried J; Baumgart J; Wüllner U; Weller M
Int J Oncol; 2002 Jul; 21(1):213-20. PubMed ID: 12063571
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
18. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
20. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
Mizutani Y; Yoshida O
Cancer; 1994 Feb; 73(3):730-7. PubMed ID: 8299097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
